Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Monday July 8

I - I

Monday

MoPeB313o Impact of HIV resistance testing guidelines on
detection of Wild Type Virus (WTV) in a clinic
cohort
B Max, S Badri, D Barker, 0 M Falusi
(United States)
MoPeB3131 An audit of the effectiveness of genotypic antiretroviral resistance testing in the management
of HIV-1 infected patients
C Y W Tong, R Kulasegaram, I Chrystie, I Mullen,
A De Ruiter, S O'Shea (United Kingdom)
MoPeB3132 An easily upgradable database software-tool for
rules-based resistance mutation interpretation
I Sutinen, I Suni, K Liitsola, M Ristola,
V Zetterberg, P Leinikki, H BrummerKorvenkontio, M 0 Salminen (Finland)
MoPeB3133 Minisequencing as a new method to detect HIV-1
antiviral drug resistance mutations
V Zetterberg, K Liitsola, I Suni, I Sutinen,
M Ristola, N Kokkonen, H BrummerKorvenkontio, M 0 Salminen (Finland)
MoPeB3134 HIV drug resistance assays: genotyping versus
virtual-phenotyping in HIV-experienced patients
V Micheli MR Gismondo, P Meraviglia,
L Valsecchi, A Cargnel (Italy)
MoPeB3135 Characterization of rebound virus emerged in
human immunodeficiency virus type 1 infected
patient during highly active antiretroviral therapy
H mori, Y Kojima, T Kawahata, T Otake, I Oishi
(apan)
MoPeB3136 Drug-associated resistance mutations in plasma
and peripheral blood mononuclear cells in
treatment-experienced patients at the time of
genotypic guided changing therapy
E Nicastri L Sarmati, I Uccella, M Andreoni,
L Palmisano, S Vella, R Amici, M C Galluzzo,
V Vullo, G d'Ettorre, S G Parisi, E Concia (Italy)
MoPeB3137 A method for determination of HIV-1 viral load
without the use of PCR
A Malmsten, X W Shao, K Aperia, CF R Klillander,
TLeitner, JS Gronowitz (Sweden)
MoPeB3138 Prevalence and clinical significance of the 184V
mutation in HIV-infected patients with discordant
response to Highly Active Antiretroviral Therapy
L Sarmati, I Uccella, M Andreoni, E Nicastri,
S G Parisi, E Concia, G d'Ettorre, V Vullo,
L Palmisano, M C Galluzzo, M Andreotti, S Vella
(Italy)
MoPeB3139 Viral load decay after storage at room
temperature: implications for antiviral resistance
genotyping
C Polo', J Niubb', A Mielnichuk', D Kaptoul,
M Friesenhahn2, D Hendricks2, R Martin',
j L Pdrez' ('Spain; 2United States)
MoPeB314o HIV resistance in a Hispanic treatmentexperienced population and clinical response
after genotype-guided treatment change
EArroyo,C R Tampe, C Rivera-Vazquez,
G Gonzalez, S Soavedra, C H Ramirez-Ronda
(Puerto Rico)
MoPeB3141 The use of genotype resistance testing in HIVinfected pediatric patients
I Herandez, E Folch, S Nesheim, A Caliendo,
I Lennox, C del Rio (United States)
MoPeB3142 Incidence and nature of phenotype-genotype
discordance in a clinical setting: maximizing the
utility of resistance testing
N Parkin, C Chappey, L Maroldo, I Arocha,

T Fralich, S Schrader, D Ward, M Wohlfeiler,
M Bates (United States)

MoPeB3143 Study of resistance to protease inhibitors in HIV-1
strains isolated in the Czech Republic
M Linka, M Bruckova, J Vandasova, M Stankova,
J Prejdova, R Ramiadamanana (Czech Republic)
MoPeB3144 Influence of the M184V mutation on virologic
outcome of highly active antiretroviral therapy
with or without ddl
B G Gazzard', A Pozniak', M Peeters2,
R Hoetelmans2, N M Graham3
('United Kingdom; 2Belgium; 3United States)
MoPeB3145 Chimeric Virus Technology (CVT) for HIV envgenes to evaluate the resistance/susceptibility
profile towards HIV entry inhibitors
V Fikkert, P Cherepanov, K Van Laethem,
A Hantson, B Van Remoortel, C Pannecouque,
E De Clercq, Z Debyser, A M Vandamme,
M Witvrouw (Belgium)
MoPeB3146 Construction of molecular infectious clones
(MICs) and viral panels with defined mixture
composition to specify guidelines for editing
mixed base positions during population
sequencing of HIV-1
M L Short, J Chen, A ] Devitt, M R Furtado,
R C Brown (United States)
MoPeB3147 HIV-1 subtyping using a commercially-available
sequencing kit and integral analytical software
can be convenient and accurate
M H Harzic, C M Malbrunot, F P Pougade,
A D Dublanchet, B D Dubeaux, F S Simon (France)
MoPeB3148 External quality assurance for genotypic
antiretroviral resistance testing
S A Land, D C Sayer, C]J Birch, S Emery, G Hales,
EM Dax for The HIV Resistance Working Group,
(Australia)
MoPeB3149 The HIV-infected traveller
/ E Solit, M Sano, K Kain (Canada)
MoPeB315o Prophylaxis for Sexual Violence post-exposure
V K Rosa, N T Barcellos, S S Schuh (Brazil)
MoPeB3151 Effectiveness of a Ryan White funded program in
providing care to HIV infected patients
P Keiser, B Blake, G Sinclair, G Koen, J Sandoval,
M Figuero, S Moreno (United States)
MoPeB3152 Creating an innovative care model for children
living with HIV/AIDS in Uganda
N A A Nakayiwa (Uganda)
MoPeB3153 Hospitalisation on Palliative Care: which is the
attendance profile for AIDS home care public
service (HCPS) in Uganda?
K G E Kavuma, KS Kapere, K M A kaddu Mukasa
Anne, 0 M Okia (Uganda)
MoPeB3154 Mental health diagnoses and medications in HIV
patients receiving care in publicly-funded clinics
L M Kunches L R Hirschhorn, N E Reinhalter,
I B DeCristofaro, Musolino, P B Lawrence,
I F McGuire, M A ACTNow Working Group
(United States)
MoPeB3155 Handgrip strength: an indicator of general body
weakness in HIV/AIDS individuals
TN Smiley, H A Radwan, R ] Cowie
(United States)
MoPeB3156 Comparison of the efficacy of Hepatitis A and
Hepatitis B vaccination in HIV infected patients
C Yoon, L Tiffany, D Durst, C Wilson, S Sledz,
B Pedro, A Barton, L Estok, D Smith, M Doyle,
P T Smith (United States)
MoPeB3157 The HIV Curriculum Project: training family
practice residents in the new age of AIDS

JL Feldman, M Miner, M Millis, E Coleman
(United States)

Final Program